Nie ka\u017ed\u00fd reaguje na rovnak\u00fd liek rovnako. \u00da\u010dinnos\u0165 liekov a ich ved\u013eaj\u0161ie \u00fa\u010dinky sa l\u00ed\u0161ia v z\u00e1vislosti od jednotlivca a s\u00fa ovplyvnen\u00e9 genetikou, zdravotnou anamn\u00e9zou, vekom a \u017eivotn\u00fdm \u0161t\u00fdlom.<\/p>\n\n\n\n
Farmakogenomika je nov\u00e1 vedeck\u00e1 oblas\u0165, ktor\u00e1 sa r\u00fdchlo rozv\u00edja v\u010faka svojej schopnosti minimalizova\u0165 d\u00e1vkovanie met\u00f3dou pokus-omyl a zlep\u0161ova\u0165 v\u00fdsledky lie\u010dby. Kombinuje \u0161t\u00fadium liekov (farmakol\u00f3gia) so \u0161t\u00fadiom g\u00e9nov (genomika). Ide o siln\u00fa kombin\u00e1ciu: umo\u017e\u0148uje vedcom predpoveda\u0165, ako m\u00f4\u017eu g\u00e9ny \u010dloveka ovplyvni\u0165 jeho reakciu na liek, a umo\u017e\u0148uje lek\u00e1rovi predp\u00edsa\u0165 liek, ktor\u00fd je pre dan\u00e9ho jednotlivca najvhodnej\u0161\u00ed.<\/p>\n\n\n\n
Farmakogenomika sa zameriava na prisp\u00f4sobenie liekov a d\u00e1vkovania jednotliv\u00fdm pacientom pre maxim\u00e1lnu \u00fa\u010dinnos\u0165 a minim\u00e1lne ved\u013eaj\u0161ie \u00fa\u010dinky, \u010do je zn\u00e1me ako presn\u00e1 medic\u00edna. V s\u00fa\u010dasnosti je presn\u00e1 medic\u00edna st\u00e1le v relat\u00edvne ran\u00fdch \u0161t\u00e1di\u00e1ch a je dostupn\u00e1 len pre ur\u010dit\u00e9 ochorenia. S pokrokom v\u00fdskumu m\u00e1 v\u0161ak farmakogenomika potenci\u00e1l transformova\u0165 lek\u00e1rsku starostlivos\u0165.<\/p>\n\n\n\n
Ako m\u00f4\u017eu niekoho g\u00e9ny zmeni\u0165 sp\u00f4sob, ak\u00fdm reaguje na liek?<\/strong><\/p>\n\n\n\n Mnoh\u00e9 lieky funguj\u00fa tak, \u017ee sa via\u017eu na receptory na povrchu buniek. Typy receptorov s\u00fa ur\u010den\u00e9 DNA \u010dloveka a r\u00f4zne receptory reaguj\u00fa na lieky odli\u0161ne. Liek m\u00f4\u017ee by\u0165 vysoko \u00fa\u010dinn\u00fd pre \u010dloveka s jedn\u00fdm typom receptora, zatia\u013e \u010do nie tak \u00fa\u010dinn\u00fd pre niekoho s in\u00fdm typom receptora. Zisten\u00edm, ak\u00fd typ receptorov m\u00e1 pacient, m\u00f4\u017eu lek\u00e1ri ur\u010di\u0165 najvhodnej\u0161\u00ed liek a d\u00e1vkovanie pre dan\u00e9ho pacienta.<\/p>\n\n\n\n Niekedy m\u00f4\u017ee DNA \u010dloveka z neho urobi\u0165 siln\u00e9ho kandid\u00e1ta na ur\u010dit\u00fd druh lieku; inokedy DNA \u010dloveka ukazuje, \u017ee na konkr\u00e9tny liek nebude dobre reagova\u0165 alebo m\u00f4\u017ee potrebova\u0165 ni\u017e\u0161iu d\u00e1vku, aby sa minimalizovali ved\u013eaj\u0161ie \u00fa\u010dinky. Namiesto pou\u017e\u00edvania jedn\u00e9ho lieku na lie\u010dbu v\u0161etk\u00fdch pacientov s ur\u010dit\u00fdm ochoren\u00edm m\u00f4\u017eu lek\u00e1ri prisp\u00f4sobi\u0165 lieky a d\u00e1vkovanie jednotlivcovi.<\/p>\n\n\n\n Ako sa pacient podrob\u00ed genetick\u00e9mu testovaniu pre prec\u00edznu medic\u00ednu?<\/strong><\/p>\n\n\n\n \u0160t\u00fadie uk\u00e1zali, \u017ee \u013eudia s g\u00e9nom 98% m\u00f4\u017eu ma\u0165 genomick\u00fd variant, ktor\u00fd m\u00f4\u017ee ovplyvni\u0165 ich reakciu na lieky. Aby sa zistilo, \u010di \u00e1no, pacient m\u00f4\u017ee podst\u00fapi\u0165 genetick\u00fd test, ktor\u00fd h\u013ead\u00e1 g\u00e9n alebo nieko\u013eko g\u00e9nov, ktor\u00e9 m\u00f4\u017eu ovplyvni\u0165, ktor\u00fd liek je pre neho najlep\u0161\u00ed. Toto sa d\u00e1 urobi\u0165 pomocou vzorky krvi alebo v\u00fdteru z l\u00edc.<\/p>\n\n\n\n Genomick\u00e9 testovanie sa zvy\u010dajne vykon\u00e1va, ke\u010f je osoba prv\u00fdkr\u00e1t diagnostikovan\u00e1, ke\u010f liek nezaberie alebo ke\u010f ne\u017eiaduce \u00fa\u010dinky nar\u00fa\u0161aj\u00fa lie\u010dbu.<\/p>\n\n\n\n Ak\u00fd je s\u00fa\u010dasn\u00fd stav farmakogenomiky pre z\u00e1va\u017en\u00e9 a komplexn\u00e9 ochorenia?<\/strong><\/p>\n\n\n\n V s\u00fa\u010dasnosti je pou\u017eitie farmakogenomiky do istej miery obmedzen\u00e9. Po prv\u00e9, testy m\u00f4\u017eu by\u0165 drah\u00e9 a nie s\u00fa \u0161iroko dostupn\u00e9. Po druh\u00e9, farmakogenomika bola schv\u00e1len\u00e1 iba na lie\u010dbu nieko\u013ek\u00fdch zdravotn\u00fdch probl\u00e9mov. Medzi ochorenia, ktor\u00e9 profitovali z pokroku vo farmakogenomike, patria:<\/p>\n\n\n\n \u2022 Niektor\u00e9 druhy rakoviny vr\u00e1tane rakoviny prsn\u00edka, rakoviny hrub\u00e9ho \u010dreva a ak\u00fatnej lymfoblastickej leuk\u00e9mie (ALL)<\/p>\n\n\n\n \u2022 Depresia<\/p>\n\n\n\n \u2022 HIV<\/p>\n\n\n\n \u2022 Srdcov\u00e9 choroby<\/p>\n\n\n\n \u2022 Vysok\u00fd cholesterol<\/p>\n\n\n\n Klinick\u00e9 \u0161t\u00fadie ka\u017ed\u00fd rok odha\u013euj\u00fa nov\u00e9 vyu\u017eitie farmakogenomiky a o\u010dak\u00e1va sa, \u017ee jej dostupnos\u0165 a pou\u017eite\u013enos\u0165 sa bude neust\u00e1le zvy\u0161ova\u0165 a bude zah\u0155\u0148a\u0165 nov\u00e9 stavy a choroby. Nie ka\u017ed\u00fd reaguje na rovnak\u00fd liek rovnako. \u00da\u010dinnos\u0165 liekov a ved\u013eaj\u0161ie \u00fa\u010dinky sa l\u00ed\u0161ia v z\u00e1vislosti od jednotlivca a s\u00fa ovplyvnen\u00e9 genetikou, zdravotnou anamn\u00e9zou, vekom a \u017eivotn\u00fdm \u0161t\u00fdlom.<\/p>\n\n\n\n Farmakogenomika je nov\u00e1 vedeck\u00e1 oblas\u0165, ktor\u00e1 sa r\u00fdchlo rozv\u00edja v\u010faka svojej schopnosti minimalizova\u0165 d\u00e1vkovanie met\u00f3dou pokus-omyl a zlep\u0161ova\u0165 v\u00fdsledky lie\u010dby. Kombinuje \u0161t\u00fadium liekov (farmakol\u00f3gia) so \u0161t\u00fadiom g\u00e9nov (genomika). Ide o siln\u00fa kombin\u00e1ciu: umo\u017e\u0148uje vedcom predpoveda\u0165, ako m\u00f4\u017eu g\u00e9ny \u010dloveka ovplyvni\u0165 jeho reakciu na liek, a umo\u017e\u0148uje lek\u00e1rovi predp\u00edsa\u0165 liek, ktor\u00fd je pre dan\u00e9ho jednotlivca najvhodnej\u0161\u00ed.<\/p>\n\n\n\n Farmakogenomika sa zameriava na prisp\u00f4sobenie liekov a d\u00e1vkovania jednotliv\u00fdm pacientom pre maxim\u00e1lnu \u00fa\u010dinnos\u0165 a minim\u00e1lne ved\u013eaj\u0161ie \u00fa\u010dinky, \u010do je zn\u00e1me ako presn\u00e1 medic\u00edna. V s\u00fa\u010dasnosti je presn\u00e1 medic\u00edna st\u00e1le v relat\u00edvne ran\u00fdch \u0161t\u00e1di\u00e1ch a je dostupn\u00e1 len pre ur\u010dit\u00e9 ochorenia. S pokrokom v\u00fdskumu m\u00e1 v\u0161ak farmakogenomika potenci\u00e1l transformova\u0165 lek\u00e1rsku starostlivos\u0165.<\/p>\n\n\n\n Ako m\u00f4\u017eu niekoho g\u00e9ny zmeni\u0165 sp\u00f4sob, ak\u00fdm reaguje na liek?<\/strong><\/p>\n\n\n\n Mnoh\u00e9 lieky funguj\u00fa tak, \u017ee sa via\u017eu na receptory na povrchu buniek. Typy receptorov s\u00fa ur\u010den\u00e9 DNA \u010dloveka a r\u00f4zne receptory reaguj\u00fa na lieky odli\u0161ne. Liek m\u00f4\u017ee by\u0165 vysoko \u00fa\u010dinn\u00fd pre \u010dloveka s jedn\u00fdm typom receptora, zatia\u013e \u010do nie tak \u00fa\u010dinn\u00fd pre niekoho s in\u00fdm typom receptora. Zisten\u00edm, ak\u00fd typ receptorov m\u00e1 pacient, m\u00f4\u017eu lek\u00e1ri ur\u010di\u0165 najvhodnej\u0161\u00ed liek a d\u00e1vkovanie pre dan\u00e9ho pacienta.<\/p>\n\n\n\n Niekedy m\u00f4\u017ee DNA \u010dloveka z neho urobi\u0165 siln\u00e9ho kandid\u00e1ta na ur\u010dit\u00fd druh lieku; inokedy DNA \u010dloveka ukazuje, \u017ee na konkr\u00e9tny liek nebude dobre reagova\u0165 alebo m\u00f4\u017ee potrebova\u0165 ni\u017e\u0161iu d\u00e1vku, aby sa minimalizovali ved\u013eaj\u0161ie \u00fa\u010dinky. Namiesto pou\u017e\u00edvania jedn\u00e9ho lieku na lie\u010dbu v\u0161etk\u00fdch pacientov s ur\u010dit\u00fdm ochoren\u00edm m\u00f4\u017eu lek\u00e1ri prisp\u00f4sobi\u0165 lieky a d\u00e1vkovanie jednotlivcovi.<\/p>\n\n\n\n Ako sa pacient podrob\u00ed genetick\u00e9mu testovaniu pre prec\u00edznu medic\u00ednu?<\/strong><\/p>\n\n\n\n \u0160t\u00fadie uk\u00e1zali, \u017ee \u013eudia s g\u00e9nom 98% m\u00f4\u017eu ma\u0165 genomick\u00fd variant, ktor\u00fd m\u00f4\u017ee ovplyvni\u0165 ich reakciu na lieky. Aby sa zistilo, \u010di \u00e1no, pacient m\u00f4\u017ee podst\u00fapi\u0165 genetick\u00fd test, ktor\u00fd h\u013ead\u00e1 g\u00e9n alebo nieko\u013eko g\u00e9nov, ktor\u00e9 m\u00f4\u017eu ovplyvni\u0165, ktor\u00fd liek je pre neho najlep\u0161\u00ed. Toto sa d\u00e1 urobi\u0165 pomocou vzorky krvi alebo v\u00fdteru z l\u00edc.<\/p>\n\n\n\n Genomick\u00e9 testovanie sa zvy\u010dajne vykon\u00e1va, ke\u010f je osoba prv\u00fdkr\u00e1t diagnostikovan\u00e1, ke\u010f liek nezaberie alebo ke\u010f ne\u017eiaduce \u00fa\u010dinky nar\u00fa\u0161aj\u00fa lie\u010dbu.<\/p>\n\n\n\n Ak\u00fd je s\u00fa\u010dasn\u00fd stav farmakogenomiky pre z\u00e1va\u017en\u00e9 a komplexn\u00e9 ochorenia?<\/strong><\/p>\n\n\n\n V s\u00fa\u010dasnosti je pou\u017eitie farmakogenomiky do istej miery obmedzen\u00e9. Po prv\u00e9, testy m\u00f4\u017eu by\u0165 drah\u00e9 a nie s\u00fa \u0161iroko dostupn\u00e9. Po druh\u00e9, farmakogenomika bola schv\u00e1len\u00e1 iba na lie\u010dbu nieko\u013ek\u00fdch zdravotn\u00fdch probl\u00e9mov. Medzi ochorenia, ktor\u00e9 profitovali z pokroku vo farmakogenomike, patria:<\/p>\n\n\n\n \u2022 Niektor\u00e9 druhy rakoviny vr\u00e1tane rakoviny prsn\u00edka, rakoviny hrub\u00e9ho \u010dreva a ak\u00fatnej lymfoblastickej leuk\u00e9mie (ALL)<\/p>\n\n\n\n \u2022 Depresia<\/p>\n\n\n\n \u2022 HIV<\/p>\n\n\n\n \u2022 Srdcov\u00e9 choroby<\/p>\n\n\n\n \u2022 Vysok\u00fd cholesterol<\/p>\n\n\n\n Klinick\u00e9 \u0161t\u00fadie ka\u017ed\u00fd rok odha\u013euj\u00fa nov\u00e9 vyu\u017eitie farmakogenomiky a o\u010dak\u00e1va sa, \u017ee jej dostupnos\u0165 a pou\u017eite\u013enos\u0165 sa bude neust\u00e1le zvy\u0161ova\u0165 a bude zah\u0155\u0148a\u0165 nov\u00e9 stavy a ochorenia.<\/p>\n\n\n\n Ak\u00e1 je n\u00e1dej pre bud\u00facnos\u0165 farmakogenomiky?<\/strong><\/p>\n\n\n\n Skuto\u010dne sme na pokraji individualizovanej medic\u00edny. Ke\u010f\u017ee sa medic\u00edna st\u00e1va \u010doraz personalizovanej\u0161ou, lek\u00e1ri bud\u00fa schopn\u00ed lep\u0161ie predpoveda\u0165, ktor\u00fd liek je pre ka\u017ed\u00e9ho \u010dloveka najvhodnej\u0161\u00ed. Farmakogenomika spolupracuje s pr\u00edbuzn\u00fdmi oblas\u0165ami medic\u00edny vr\u00e1tane epigenetiky (ktor\u00e1 sk\u00fama, ako bunky ovplyv\u0148uj\u00fa aktivitu g\u00e9nov), \u0161t\u00fadi\u00ed mikrobi\u00f3mu (ktor\u00e9 sk\u00famaj\u00fa, ako mikroorganizmy v na\u0161om tele ovplyv\u0148uj\u00fa na\u0161e zdravie) a nutrigenomiky (ktor\u00e1 sk\u00fama, ako \u017eiviny ovplyv\u0148uj\u00fa genetick\u00fa v\u00fdbavu). Tieto \u0161t\u00fadie spolo\u010dne umo\u017enia lek\u00e1rom lep\u0161ie pochopi\u0165, ako priradi\u0165 spr\u00e1vny liek spr\u00e1vnej osobe. To m\u00f4\u017ee vies\u0165 k lep\u0161\u00edm zdravotn\u00fdm v\u00fdsledkom a men\u0161iemu po\u010dtu ne\u017eiaducich ved\u013eaj\u0161\u00edch \u00fa\u010dinkov pre pacientov, \u010do vytvor\u00ed n\u00e1dej na \u0161\u0165astnej\u0161\u00ed a zdrav\u0161\u00ed zajtraj\u0161ok.<\/p>\n\n\n\n Ak\u00e1 je n\u00e1dej pre bud\u00facnos\u0165 farmakogenomiky?<\/strong><\/p>\n\n\n\n Skuto\u010dne sme na pokraji individualizovanej medic\u00edny. Ke\u010f\u017ee sa medic\u00edna st\u00e1va \u010doraz personalizovanej\u0161ou, lek\u00e1ri bud\u00fa schopn\u00ed lep\u0161ie predpoveda\u0165, ktor\u00fd liek je pre ka\u017ed\u00e9ho \u010dloveka najvhodnej\u0161\u00ed. Farmakogenomika spolupracuje s pr\u00edbuzn\u00fdmi oblas\u0165ami medic\u00edny vr\u00e1tane epigenetiky (ktor\u00e1 sk\u00fama, ako bunky ovplyv\u0148uj\u00fa aktivitu g\u00e9nov), \u0161t\u00fadi\u00ed mikrobi\u00f3mu (ktor\u00e9 sk\u00famaj\u00fa, ako mikroorganizmy v na\u0161om tele ovplyv\u0148uj\u00fa na\u0161e zdravie) a nutrigenomiky (ktor\u00e1 sk\u00fama, ako \u017eiviny ovplyv\u0148uj\u00fa genetick\u00fa v\u00fdbavu). Tieto \u0161t\u00fadie spolo\u010dne umo\u017enia lek\u00e1rom lep\u0161ie pochopi\u0165, ako priradi\u0165 spr\u00e1vny liek spr\u00e1vnej osobe. To m\u00f4\u017ee vies\u0165 k lep\u0161\u00edm zdravotn\u00fdm v\u00fdsledkom a men\u0161iemu po\u010dtu ne\u017eiaducich ved\u013eaj\u0161\u00edch \u00fa\u010dinkov pre pacientov, \u010do vytvor\u00ed n\u00e1dej na \u0161\u0165astnej\u0161\u00ed a zdrav\u0161\u00ed zajtraj\u0161ok.<\/p>","protected":false},"excerpt":{"rendered":" Not everyone responds to the same medication in the same way. Medication effectiveness and side effects vary by individual, influenced by genetics, health history, age, and lifestyle. Pharmacogenomics is a new field of science that is growing rapidly due to its ability to minimize trial-and-error dosing and improve treatment outcomes. It combines the study of […]<\/p>\n","protected":false},"author":1,"featured_media":1926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[78,132,130,131,133],"class_list":["post-1924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicine","tag-medical-research","tag-personalized-medicine","tag-pharmacogenomics","tag-precision-medicine","tag-treatment"],"_links":{"self":[{"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/posts\/1924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/comments?post=1924"}],"version-history":[{"count":0,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/posts\/1924\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/media\/1926"}],"wp:attachment":[{"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/media?parent=1924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/categories?post=1924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.worldcare.com\/sk\/wp-json\/wp\/v2\/tags?post=1924"}],"curies":[{"name":"pracovn\u00fd list","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}